Mirae Asset Global Etfs Holdings Ltd. Inozyme Pharma, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 24,405 shares of INZY stock, worth $98,108. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,405Holding current value
$98,108% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
94Shares Held
52.5MCall Options Held
17.6KPut Options Held
2.7K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.73MShares$23 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18.1 Million18.06% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.2 Million1.06% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.94MShares$15.8 Million0.31% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.7MShares$14.9 Million0.51% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...